RankAlpha logo
Back to Rankings

AVTR

AvantorD
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The best bull read is that Q1 reset expectations low enough for a modest beat/reaffirm quarter to matter: management cited improved Bioscience execution, VWR stabilization, and early benefit from the Revival program, while the packet's median analyst target of $10.6333 sits above the $7.99 anchor price.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.5.
What can break
Free cash flow fell to $25.2 million from $82.1 million in the prior-year quarter, and cash and cash equivalents declined to $279.3 million from $365.4 million at December 31, 2025. [#10-Q-2026-04-29]
Momentum
32
Value
66
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.80 · Bull $10.20 · Bear $6.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.63
Why
Momentum32 · Δ7d +14.5
Value66 · Δ7d -0.5
Sentiment45 · Δ7d -9.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
32
34% active weight
Current posture
7d trendImproving
Δ7d
+14.5
Δ21d
+26.6
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.2
Sentiment
45
33% active weight
Current posture
7d trendSoftening
Δ7d
-9.8
Δ21d
-6.8
Why this grade

Composite grade D. Momentum 32.1 / Value 65.6 / Sentiment 45.2

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$6.14B
Beta
0.94
Shares Out
681.81M
P/E (TTM)
12.5
P/S (TTM)
1.23
P/FCF (TTM)
15.48
Rev YoY
-5.3%
EPS YoY
-1333.8%
Gross Margin
+33.1%
Op Margin
+4.0%
Net Debt
$3.79B
Current Ratio
1.49
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology